A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs ASLAN-004 (Primary) ; ASLAN-004 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors ASLAN Pharmaceuticals
- 01 Jul 2019 Planned End Date changed from 30 Sep 2019 to 30 Nov 2019.
- 01 Jul 2019 Planned primary completion date changed from 20 May 2019 to 30 Nov 2019.
- 04 Jun 2019 Results presented in an ASLAN Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History